New stock news | Ying En Bio is listed on the Hong Kong stock market and has been approved by the China Securities Regulatory Commission.

On January 21, the International Cooperation Department of the China Securities Regulatory Commission issued a notice on the overseas issuance and listing filing of Duality Biotherapeutics, Inc. The company plans to issue no more than 26,106,596 shares of overseas listed ordinary shares and list on the Hong Kong Stock Exchange. According to the disclosure of the Hong Kong Stock Exchange on August 26, 2024, Duality Biotherapeutics submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley, Jefferies, and CITIC Securities as joint sponsors. According to the prospectus, Duality Biotherapeutics is a global leader in the field of Antibody-Drug Conjugates (ADCs), dedicated to developing a new generation of innovative ADC drugs for patients with cancer and autoimmune diseases. The company has established a variety of differentiated pipelines using its own ADC technology platform and is advancing these pipelines with the goal of revolutionizing cancer treatment and providing therapies that can significantly improve treatment outcomes for patients worldwide. According to Duality Biotherapeutics, since its establishment in 2019, the company has built an innovative and differentiated pipeline consisting of 12 ADC candidate drugs developed in-house, including six clinical-stage ADCs with potential in indications with unmet clinical needs, all of which rank among the global leaders in terms of overall or major indication development progress according to Frost & Sullivan; two next-generation bispecific ADCs (BsADCs) and one ADC for treating autoimmune diseases (selfimmune ADC) are expected to enter clinical stages from 2024 to 2026; and several other preclinical ADCs.